GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (HKSE:01349) » Definitions » Debt-to-Revenue

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (HKSE:01349) Debt-to-Revenue : 0.01 (As of Jun. 2024)


View and export this data going back to 2002. Start your Free Trial

What is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was HK$3.5 Mil. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was HK$9.7 Mil. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's annualized Revenue for the quarter that ended in Jun. 2024 was HK$1,121.7 Mil. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's annualized Debt-to-Revenue for the quarter that ended in Jun. 2024 was 0.01.


Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Debt-to-Revenue Historical Data

The historical data trend for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Debt-to-Revenue Chart

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.15 0.02 0.03 0.12 0.02

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Quarterly Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.03 0.02 0.01 -

Competitive Comparison of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Debt-to-Revenue falls into.



Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(6.923 + 11.98) / 930.514
=0.02

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's annualized Debt-to-Revenue for the quarter that ended in Jun. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(3.489 + 9.671) / 1121.66
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Jun. 2024) Revenue data.


Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Business Description

Traded in Other Exchanges
Address
308 Cailun Road, Zhangjiang Hi-Tech Park, Pudong, Shanghai, CHN, 201210
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd is engaged in the research, development, manufacturing, and sale of biopharmaceutical products. Its product portfolio includes ALA (Aminolevulinic acid Hydrochloride); FuMeiDa and Libord. Geographically, it derives revenue from Mainland China.
Executives
Invesco Hong Kong Limited 2102 Investment manager
Shanghai Pharmaceuticals Holding Co., Ltd.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Headlines

No Headlines